--- title: "ArriVent BioPharma (AVBP) news: offering" url: "https://aibio.space/companies/arrivent-biopharma/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "AVBP offering news: ArriVent BioPharma files for up to $250,000,000 in at-the-market stock sales. ArriVent BioPharma, Inc. (NASDAQ: AVBP), United States." --- AVBP ArriVent BioPharma, Inc. NASDAQ · United States # ArriVent BioPharma (AVBP) news AVBP offering news Financings · 2026-05-11 ## [ArriVent BioPharma files for up to $250,000,000 in at-the-market stock sales](https://aibio.space/news/arrivent-biopharma-files-up-250-000-000-market-stock-sales/) ArriVent BioPharma, Inc. filed a prospectus supplement on May 11, 2026 under its existing sales agreement with Jefferies LLC. The last reported sale price was $29.50 per share on May 8, 2026. ## Latest ArriVent BioPharma news 1. 2025-02-03 Financings [ArriVent BioPharma files automatic shelf with $250,000,000 ATM sales agreement](https://aibio.space/news/arrivent-biopharma-files-automatic-shelf-250-000-000-atm-sales/) Jefferies is the sales agent. ArriVent's stock last sold at $29.09 per share on January 30, 2025. ## ArriVent BioPharma at a glance - **Ticker**: AVBP - **Listing**: NASDAQ - **Country**: United States - **Cash, Jun 30, 2026**: $373.1 million ### Related companies - [Scilex Holding](https://aibio.space/companies/scilex/) NASDAQ: SCLX - [Burzynski Research Institute](https://aibio.space/companies/burzynski-research-institute/) OTC: BZYR - [iBio](https://aibio.space/companies/ibio/) NASDAQ: IBIO - [Nutra Pharma](https://aibio.space/companies/nutra-pharma/) OTC: NPHC - [Earth Science Tech](https://aibio.space/companies/earth-science-tech/) OTC: ETST - [PharmaCyte Biotech](https://aibio.space/companies/pharmacyte-biotech/) NASDAQ: PMCB - [Definium Therapeutics](https://aibio.space/companies/definium-therapeutics/) NASDAQ: DFTX - [Therapeutic Solutions International](https://aibio.space/companies/therapeutic-solutions-international/) OTC: TSOI ### Also on NASDAQ - [Alnylam Pharmaceuticals](https://aibio.space/companies/alnylam-pharmaceuticals/) ALNY - [GH Research](https://aibio.space/companies/gh-research/) GHRS - [OmniAb](https://aibio.space/companies/omniab/) OABI - [Oric Pharmaceuticals](https://aibio.space/companies/oric-pharmaceuticals/) ORIC - [Aardvark Therapeutics](https://aibio.space/companies/aardvark-therapeutics/) AARD - [vTv Therapeutics](https://aibio.space/companies/vtv-therapeutics/) VTVT ## ArriVent BioPharma annual financials | Line | FY2025 | FY2024 | |---|---|---| | Research and development | [$153.4 million](https://www.sec.gov/Archives/edgar/data/1868279/000110465926024127/) | [$79.0 million](https://www.sec.gov/Archives/edgar/data/1868279/000110465926024127/) | | Net income (loss) | [-$166.3 million](https://www.sec.gov/Archives/edgar/data/1868279/000110465926024127/) | [-$80.5 million](https://www.sec.gov/Archives/edgar/data/1868279/000110465926024127/) | | Cash from operations | [-$160.6 million](https://www.sec.gov/Archives/edgar/data/1868279/000110465926024127/) | [-$70.2 million](https://www.sec.gov/Archives/edgar/data/1868279/000110465926024127/) | | Cash and equivalents | [$45.5 million](https://www.sec.gov/Archives/edgar/data/1868279/000110465926094902/) | [$74.3 million](https://www.sec.gov/Archives/edgar/data/1868279/000110465926024127/) | | Short-term investments | [$267.3 million](https://www.sec.gov/Archives/edgar/data/1868279/000110465926094902/) | [$144.6 million](https://www.sec.gov/Archives/edgar/data/1868279/000110465926024127/) | Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $154.7 million, plus short-term investments of $218.4 million, $373.1 million in all. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about ArriVent BioPharma Has ArriVent BioPharma raised money recently? Our latest story on this, dated May 11, 2026: "ArriVent BioPharma files for up to $250,000,000 in at-the-market stock sales". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/arrivent-biopharma-files-up-250-000-000-market-stock-sales/). What is the ticker symbol of ArriVent BioPharma? ArriVent BioPharma, Inc. trades under the ticker AVBP on NASDAQ. Where is ArriVent BioPharma listed? ArriVent BioPharma, Inc. is listed on NASDAQ. What is the SEC CIK of ArriVent BioPharma? The SEC Central Index Key (CIK) for ArriVent BioPharma, Inc. is 1868279. Its filings are on SEC EDGAR. How many shares does ArriVent BioPharma have outstanding? 49,307,729 shares as of 2026-08-10, per the cover page of its 10-Q filed 2026-08-12. Which country or territory is ArriVent BioPharma listed under? Our directory records ArriVent BioPharma, Inc. under United States. What does ArriVent BioPharma do? Our directory classifies ArriVent BioPharma, Inc. as: Biopharma / pharmaceutical profile checked. This is a directory classification, not a description of the pipeline. What is the ISIN of ArriVent BioPharma? The ISIN recorded for ArriVent BioPharma, Inc. is US04272N1028. Does aibio.space cover ArriVent BioPharma? aibio.space lists ArriVent BioPharma, Inc. among 2,820 public biotech companies and publishes its news here as stories appear. Where is ArriVent BioPharma incorporated? SEC records list its state or country of incorporation as DE. Is ArriVent BioPharma profitable? ArriVent BioPharma, Inc. reported a net loss of $166.3 million for the fiscal year ended Dec 31, 2025, and used $160.6 million of cash in operations, per its annual report to the SEC. How much does ArriVent BioPharma spend on research and development? $153.4 million in the fiscal year ended Dec 31, 2025, per its annual report. How much cash does ArriVent BioPharma have? $373.1 million in cash and short-term investments at Jun 30, 2026, per its 10-Q. What is the latest ArriVent BioPharma (AVBP) stock news? Our latest story on ArriVent BioPharma, dated May 11, 2026: "ArriVent BioPharma files for up to $250,000,000 in at-the-market stock sales". ArriVent BioPharma, Inc. filed a prospectus supplement on May 11, 2026 under its existing sales agreement with Jefferies LLC. The last reported sale price was $29.50 per share on May 8, 2026. [Source](https://aibio.space/news/arrivent-biopharma-files-up-250-000-000-market-stock-sales/). What is ArriVent BioPharma's market cap? We do not publish live share prices. In its annual report, ArriVent BioPharma, Inc. put the market value of shares held by non-affiliates (public float) at $762.7 million as of Jun 30, 2025. ## Investor discussion: ArriVent BioPharma Members talk about ArriVent BioPharma (AVBP). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at ArriVent BioPharma, newest first. Each line links the filing it comes from. 1. 2026-05-11 Financings Reported a financing. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1868279/000110465926058700/tm2614155-1_424b5.htm) 2. 2025-07-01 Financings Reported a financing. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1868279/000110465925064736/tm2519401-1_424b5.htm) 3. 2025-03-13 Legal Reported a change of independent auditor. SEC Form 8-K (Items 4.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1868279/000155837025002912/avbp-20250311x8k.htm) 4. 2025-02-03 Financings Set up an at-the-market program to sell shares over time. SEC Form S-3ASR. [Source](https://www.sec.gov/Archives/edgar/data/1868279/000110465925008356/tm254783-1_s3asr.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:AVBP on TradingView](https://www.tradingview.com/symbols/NASDAQ-AVBP/). ## SEC filings and registration - **SEC name**: ArriVent BioPharma, Inc. - **CIK**: 1868279 - **Industry (SIC)**: Pharmaceutical Preparations (2834) - **US tickers**: AVBP (Nasdaq) - **State or country of incorporation**: DE - **Fiscal year ends**: December 31 - **Filer category**:
Emerging growth company - **Business address**: 18 CAMPUS BLVD., NEWTOWN SQUARE, PA, 19073-3269 - **Phone**: 240-780-6356 - **Shares outstanding**: 49,307,729 as of 2026-08-10 (10-Q filed 2026-08-12) ### Recent filings (8-K and 6-K are the company's own announcements) - [8-K](https://www.sec.gov/Archives/edgar/data/1868279/000110465926116736/tm2627799d1_8k.htm) filed 2026-10-19 - [8-K](https://www.sec.gov/Archives/edgar/data/1868279/000110465926115161/tm2627450d1_8k.htm) filed 2026-10-13 - [8-K](https://www.sec.gov/Archives/edgar/data/1868279/000110465926113898/tm2627092d1_8k.htm) filed 2026-10-06 - [10-Q](https://www.sec.gov/Archives/edgar/data/1868279/000110465926094902/avbp-20260630x10q.htm) filed 2026-08-12 - [8-K](https://www.sec.gov/Archives/edgar/data/1868279/000110465926094869/tm2622880d1_8k.htm) filed 2026-08-12 - [8-K](https://www.sec.gov/Archives/edgar/data/1868279/000110465926076352/tm2618466d1_8k.htm) filed 2026-06-22 - [8-K](https://www.sec.gov/Archives/edgar/data/1868279/000110465926058706/tm2614177d1_8k.htm) filed 2026-05-11 - [424B5](https://www.sec.gov/Archives/edgar/data/1868279/000110465926058700/tm2614155-1_424b5.htm) filed 2026-05-11 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001868279), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details ArriVent BioPharma, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker AVBP, recorded under United States. The directory classifies it as Biopharma / pharmaceutical profile checked. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: ArriVent BioPharma, Inc. - **Ticker**: AVBP - **Listing**: NASDAQ - **Country or territory**: United States - **Business scope**: Biopharma / pharmaceutical profile checked - **ISIN**: US04272N1028 - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-AVBP/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/arrivent-biopharma/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "ArriVent BioPharma (AVBP) news: offering", 2026-10-31, https://aibio.space/companies/arrivent-biopharma/